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The human major histocompatibility complex (MHC) on chromosome 6p21 is a paradigm for genomics, showing re-
markable polymorphism and striking association with immune and non-immune diseases. The complex genomic land-
scape of the MHC, notably strong linkage disequilibrium, has made resolving causal variants very challenging. A
promising approach is to investigate gene expression levels considered as tractable intermediate phenotypes in mapping
complex diseases. However, how transcription varies across the MHC, notably relative to specific haplotypes, remains
unknown. Here, using an original hybrid tiling and splice junction microarray that includes alternate allele probes, we
draw the first high-resolution strand-specific transcription map for three commonMHC haplotypes (HLA-A1-B8-Cw7-DR3,
HLA-A3-B7-Cw7-DR15, and HLA-A26-B18-Cw5-DR3-DQ2) strongly associated with autoimmune diseases including type 1
diabetes, systemic lupus erythematosus, and multiple sclerosis. We find that haplotype-specific differences in gene ex-
pression are common across the MHC, affecting 96 genes (46.4%), most significantly the zing finger protein gene ZFP57.
Differentially expressed probes are correlated with polymorphisms between haplotypes, consistent with cis effects that we
directly demonstrate for ZFP57 in a cohort of healthy volunteers (P = 1.2 3 10–14). We establish that alternative splicing is
significantly more frequent in the MHC than genome-wide (72.5% vs. 62.1% of genes, P # 1 3 10–4) and shows marked
haplotypic differences. We also unmask novel and abundant intergenic transcription involving 31% of transcribed blocks
identified. Our study reveals that the renowned MHC polymorphism also manifests as transcript diversity, and our novel
haplotype-based approach marks a new step toward identification of regulatory variants involved in the control of MHC-
associated phenotypes and diseases.
[Supplemental material is available for this article. The microarray data from this study have been submitted to the NCBI
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) under accession no. GSE22455.]
The human major histocompatibility complex (MHC), located on
chromosome 6p21 inhumans, previously referred to as the ‘‘human
leukocyte antigen (HLA) complex,’’ plays a pivotal role in immune
function (Dausset 1981). This region of 3.5 Mb is the most gene-
dense of the genome, with 230 known genes and pseudogenes
(Horton et al. 2004). It is classically divided into the class I region,
which includes genes such as HLA-A, HLA-B, and HLA-C, and the
class II region, including, for example,HLA-DP,HLA-DQ , andHLA-
DR. These classical HLA genes encode molecules involved in an-
tigen presentation and processing. The intervening MHC class III
region notably includes genes encoding a variety of proteins in-
volved in immunity including the Tumor Necrosis Factor (TNF )
superfamily, components of the complement cascade, and mo-
lecular chaperones such as heat-shock proteins. The MHC is re-
markable for its extensive polymorphism (de Bakker et al. 2006)
and ranks first for the number of associations with immune and
non-immune diseases (Shiina et al. 2004; Rioux et al. 2009). This
has raised considerable interest across disciplines, from immunol-
ogy and genetics, to medicine and evolutionary biology. Remark-
able recent advances in our understanding of the genetic basis of
common diseases have been achieved by genome-wide association
studies (GWAS) (Wellcome Trust Case Control Consortium 2007;
Manolio 2010), which have confirmed the preeminence of the
MHC in terms of the magnitude of effect, statistical confidence,
and the number of associations with autoimmune, infectious, and
inflammatory diseases, together with cancer and adverse drug ef-
fects (Conde et al. 2010; Hamza et al. 2010; Hor et al. 2010; Singer
et al. 2010).
The fine mapping of causal variants has proved challenging
for the majority of complex traits, and we rarely understand the
mechanisms through which DNA sequence polymorphisms oper-
ate (Knight et al. 2004). Their identification has been confounded
by their multiplicity, their frequency in the general population,
their modest effects, and linkage disequilibrium (LD). The latter is
most remarkable in the MHC, where it may extend over several
megabases (Ahmad et al. 2003; Yunis et al. 2003; Vandiedonck and
Knight 2009). As a result, diseases are often found to be associated
with common extended ancestral MHC haplotypes encompassing
hundreds of genes, many of which are candidates.
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Gene expression levels are considered as relevant intermediate
phenotypes in complex diseases (Vafiadis et al. 1997; Giraud et al.
2007; Cookson et al. 2009; Nica et al. 2010; Teslovich et al. 2010).
These expression phenotypes are heritable (Yan et al. 2002) and can
bemapped as quantitative traits (Emilsson et al. 2008; Cheung and
Spielman 2009). Such studies have already highlighted cis- and
trans-acting SNPs within the MHC (Dixon et al. 2007; Vandiedonck
andKnight 2009). However, these studies andmore recentRNA-seq-
based expression quantitative trait analyses (Montgomery et al. 2010;
Pickrell et al. 2010) were focused primarily on single-point mapping
of gene expression and did not account for the extended haplotypes
relating the associated polymorphisms. A particular allele can in-
deed be found on more than one haplotype. Thus, the reciprocal
question of which genes are differentially expressed betweenMHC
extended haplotypes remains essential to resolving functionally
important genetic variants as one might expect to find the disease-
related genes among the genes whose expression is specifically
modified on the risk haplotype.
Here we sought to draw for the first time amap of transcription
for the human MHC at a haplotypic resolution in which the conse-
quences of genetic variation in phase for a large contiguous chro-
mosomal region can be established.We investigated three important
haplotypes that are common in northern European populations,
are highly conserved, and show evidence of selection and important
associationswithdiseases:HLA-A1-B8-Cw7-DR3 (associatedwith type
1 diabetes, systemic lupus erythematosus and myasthenia gravis, to-
gether with other diseases including common variable immunodefi-
ciency and infectious disease susceptibility) (Price et al. 1999); A3-
B7-Cw7-DR15 (associatedwith protection from type 1 diabetes and
susceptibility tomultiple sclerosis and systemic lupus erythematosus)
(Barcellos et al. 2003; Larsen andAlper 2004); andA26-B18-Cw5-DR3-
DQ2 (associatedwith type 1 diabetes andGraves’ disease) ( Johansson
et al. 2003). These haplotypes were fully resequenced as part of the
MHCProject (Stewart et al. 2004; Traherne et al. 2006; Horton et al.
2008), but informative individuals carrying the specific haplotypes
were not included in previous expression quantitative trait studies
(Montgomery et al. 2010; Pickrell et al. 2010). In this study, we show
how gene expression profiling of individuals homozygous for the
region has allowed us to identify extensive haplotype-related tran-
scriptional differences and highlight the importance of alternative
splicing in this transcriptional diversity.
Results
The MHC array: design and validation
Tounderstandmore clearly the relationship betweenMHCsequence
variation and gene expression, we aimed to investigate how tran-
scription varies between commonly occurring haplotypes span-
ning the classical MHC, including resolution of strand-specific
transcripts and alternative splicing.Conventionalmicroarrays based
on the human reference sequence are often confounded by se-
quence variation not accounted for in probe design (Walter et al.
2007), and, to date, the difficulties of mapping reads from high-
throughput sequencing technologies to the highly polymorphic
MHC have limited the application of RNA sequencing to this ge-
nomic region. Thus, we developed a hybrid microarray for the
MHC (denoted ‘‘MHC array’’) that included alternate allele probes
to account for known sequence diversity (SupplementalMethods).
Our array design also aimed to resolve genic and intergenic tran-
scription in a strand-specific manner at high resolution by in-
cluding a strand-specific tiling path probe set together with probes
specific to known and predicted splice junctions.We sought to use
the MHC array to analyze transcription at haplotypic resolution
using lymphoblastoid cell lines (LCLs) established from individuals
MHC-homozygous for the three autoimmune disease-associated
haplotypes of interest—COX (HLA-A1-B8-Cw7-DR3), PGF (A3-B7-
Cw7-DR15), and QBL (A26-B18-Cw5-DR3-DQ2) (Horton et al.
2008).
The MHC array includes 505,686 probes of 25-mers inter-
rogating 3.5 Mb of the classical MHC between coordinates
chr6:29,748,239–33,231,091 (hg18), including 230 genes with a
total of 2755 exons (Supplemental Fig. 1). One set of 398,626 over-
lapping probes (denoted the tiling path probe set) tiles both strands
with a final resolution of 18 bases, allowing identification of any
new transcript and its transcriptional orientation. A second set of
15,348 junction probes in four replicates aimed to monitor all
knownor predicted splice events, corresponding to 1043 junctions
in the MHC class III region (12 overlapping probes on average per
junction). For any junction or tiling probe, its reverse complement
was also incorporated into the design. Importantly, alternate
probes were specifically designed for all known SNPs or segmental
duplications.
We first carried out experiments to assess the performance of
the MHC array. Our design incorporated 10,572 shared probes with
the Affymetrix Exon 1.0 ST array allowing comparison across plat-
forms for these probes. We analyzed three biological replicate sam-
ples for each of three cell lines using the customMHC array and the
Affymetrix Exon 1.0 STarray. Intensity data from the shared probes
were highly correlated for the nine samples hybridized to both
platforms (Pearson correlation coefficients ranged from 0.83 to
0.91) (Supplemental Table 1), proving that our sample preparation
and hybridization conditions were satisfactory. Interestingly, dif-
ferences between cell lines were also correlated between platforms,
suggestive of haplotypic differences (Supplemental Fig. 2). When
all probes of the MHC array were considered, the correlation co-
efficient between culture replicates ranged between 0.96 and 0.98
(Supplemental Fig. 3). In addition to the usual standard quality
controls for hybridization and sensitivity, we estimated the strand
specificity as 84.7% (64.1%) based on the observed ratios of ex-
pression between the two strands of known expressed house-
keeping genes (Supplemental Methods). We also verified the cov-
erage of full transcripts by comparing the signal intensities from
probes tagging both ends of housekeeping genes (coefficient of
variation, 13%).
To assess the signal specificity of alternate allele probes, we
compared the signal intensity of the PGF samples in the tran-
scribed regions (see below) measured on PGF-specific probes with
that measured on COX- and QBL-specific probes. We found a sig-
nificantly higher signal on PGF-specific probes (ANOVA, P = 2.43
105). We also compared the signal of the PGF samples on the 123
perfect match probes paired with probes carrying one mismatch
corresponding to the COX path. The signal was consistently higher
on perfect match probes (ANOVA with repeated measures, P = 2 3
104). We evaluated the junction probes’ performance by using
CD79A and CD79B genes that code for both main chains of the
invariant component of the B-cell receptor complex and are ex-
pressed in LCLs. The comparison of array data and quantitative
PCR data showed similar proportions between isoforms. For
CD79A, we measured a ratio of 4.96 6 0.17 between the long and
the short isoforms using the array, and of 5.35 6 0.46 by RT-PCR.
For CD79B, we obtained a ratio of 2.71 6 0.21 between the long
and the short isoforms with the array, compared to 2.846 0.48 by
RT-PCR.
Genome Research 1043
www.genome.org
The haplo-spliceo-transcriptome of the human MHC
A high-resolution strand-specific MHC transcription map
Identification of transcriptionally active regions (TARs)
Using this validated platform, we initiated experiments in which
we aimed to generate a high-resolution strand-specific transcriptomic
map of theMHC.We first verified chromosome andMHC integrity
of the selected homozygous cell lines by DNA-FISH and then ana-
lyzed RNA prepared from PGF, COX, and QBL cells grown in trip-
licate and hybridized to the MHC array. After preprocessing of all
probes, we analyzed the tiling probes on each strand, in terms of
the ‘‘shared paths’’ corresponding to probes shared and identical
between the three haplotypic sequences, and the ‘‘alternate paths,’’
which also include haplotype-specific probes for each haplotype.
Hence, a total of eight sequence paths were considered (one shared
and three haplotypic sequence paths for each strand). After signal
smoothing, we determined transcriptionally active regions (TARs)
(Bertone et al. 2004) as any 51-base windows with median signal
intensity exceeding a threshold determined by permutation (Sup-
plemental Methods). An overview of the signal across the entire re-
gion with the ‘‘shared paths’’ relative to the PGF reference assembly
sequence is provided in Supplemental Figure 4. Overlapping TARs at
a false discovery rate (FDR) of 1%weremerged to define transcribed
blocks, whose size range was similar between strands and haplo-
types (from51 to 1380bases,mean= 108.2 bases). On average, there
was one transcribed block per 1.4 kb. These are listed in Supple-
mental Table 2 including location relative to path, strand, and each
transcript as annotated in Vega, currently themost comprehensive
annotation of the MHC locus. Overall, we found that 6% of the
MHC sequence is transcribed, with an equal distribution of 2% for
transcribed blocks on the forward, reverse, or both strands.
Genic and intergenic transcription
We then sought to determine the extent of genic and intergenic
transcription based on Vega gene annotations. We defined Vega
genes as being transcribed based on the inclusion of at least one
TAR using a 5% FDR on each ‘‘alternate path.’’ Their proportion was
similar between haplotypes and remarkably high, >92% for the
genes and >70% for the pseudogenes, underscoring the accuracy of
Vega annotations for theMHC (Supplemental Table 3). An overview
of strand-specific gene transcription occurring across the MHC is
provided in the associated Figure 1 (see foldout).
In terms of intergenic transcription, a remarkably high pro-
portion (31%) of the transcribed blocks did not map to known
genes. These intergenic blocks had an average size of 69 bases
(range 51–367) in total, reaching 1.7% of the combined length of
both strands, thus corresponding to 28.3% of overall transcribed
genomic sequence length.When looking at the distribution of the
distances of these TARs to known neighboring genes, the median
was found to be 10 kb (Supplemental Fig. 5). One-half of the in-
tergenic transcribed blocks thus mapping within 10 kb of anno-
tated genes on either the 59 or the 39 side, could be new exons or
regulatory elements as suggested by previous studies using either
tiling arrays or RNA-seq (Bertone et al. 2004; Gaulton et al. 2010;
vanBakel et al. 2010). The remaining 50%of intergenic transcribed
blocks were more distant (>10 kb) and tended to cluster (>50% are
<0.9 kb apart) in regions of lower gene density (65.1% in class I,
25.5% in class II, and 9.4% in class III). Most notably, 95% of them
colocalized with repeat elements, 78% of which mapped to an Alu
sequence. This is not simply a consequence of cross-hybridization
with Alu sequences transcribed from elsewhere in the genome as
only 37% of Alu repeats covered by the array design (necessitating
probes to be of genome-wide unique sequence) overlapped a TAR.
The same proportion was found when considering recent Alu sub-
families,AluYandAluSg. Similarly, this signal could not be attributed
to edited RNAs from genome-wide Alu sequences that are wide-
spread in human, as we found that only 0.1% of probes present in
these distant intergenic TARs matched the A-to-I or C-to-U edited
RNA sequences cataloged in the comprehensive DAtabase of RNa
EDiting (Kiran and Baranov 2010). Altogether, our data support an
abundant transcriptional activity from Alu sequences in the inter-
genic regions.
Haplotype-specific transcription
Numerous genes are differentially expressed between haplotypes
Using this high-resolution, strand-specific transcriptional map of
the MHC, we addressed the issue of haplotypic-specific gene ex-
pression. First, we considered the highest resolution using TARs
generated at a conservative FDR of 1% on the ‘‘shared paths.’’ We
found that 9%, 4.6%, and 11.1% of the TARs on PGF, COX, and
QBL sequences, respectively, were identified in only one cell line,
suggesting haplotype-specific expression.
We next tested quantitative differences in expression levels. To
this end, we used the probes from the ‘‘alternate paths’’ matching
exactly the haplotypic sequence of the corresponding cell line,
grouped into metaprobesets based on Vega annotations. Moreover,
these metaprobesets contain 4.13 times more probes per gene than
in the Affymetrix Exon 1.0 STarray (Supplemental Fig. 6). TheMHC
array thus provides ‘‘individualized’’ gene levels with a high level of
accuracy. As shown in Supplemental Table 4, this resulted in a
somewhat different list of differentially expressed genes. Overall,
using the MHC array, we identified 96 differentially expressed
genes between the three cell lines (Fig. 1; Table 1). These included
a number of classical HLA class I (HLA-A, -B, -C, and -F ) and class II
genes (HLA-DQA2, -DQB2, -DPB1) as well as class III genes in-
cluding TNF, LTA, NCR3, and LTB. We selected 12 genes showing
haplotypic differences in expression for study by quantitative
RT-PCR and found expression level differences between the cell
lines reaching statistical significance in nine of them (Supple-
mental Fig. 7) (see below for ZFP57, HLA-DQB2, and HLA-C).
This analysis allows candidate genes to be defined for specific
haplotypes. For example, we determined genes, ordered on the chro-
mosome from telomere to centromere, that were significantly dif-
ferentially expressed (adjusted P-value < 0.05) between either COX
and PGF/QBL for the HLA-A1-B8-DR3 haplotype or between PGF
andCOX/QBL for theHLA-A3-B7-DR15haplotype.Only genes up-
or down-regulated in the same direction were selected (Table 2).
This highlights, for example, ZFP57, LTA, TNF, HLA-DQA2, and
HLA-DPB1 as showing greater than twofold differential expression
with the HLA-A1-B8-DR3 haplotype and as being important can-
didate genes to investigate further for this important disease-
associated haplotype.
Colocalization of differentially expressed probes and polymorphic SNPs
That these differences could result fromhaplotype-specific sequence
variation was supported by the correlation we found between the
location of differentially expressed probes and polymorphisms be-
tween haplotypes along the chromosome for two sets of interval
series of 10-kb windows shifted by 5 kb across the MHC (Fig. 2).
This was particularly significant (as low as P = 1.8 3 106 between
PGF and QBL, Spearman test) when the analysis was restricted
to windows including at least one gene (Supplemental Table 5).
Vandiedonck et al.
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Conversely, no correlation was found in windows lacking genes or
when testing genic windows against nonpolymorphic markers be-
tween the pairs of haplotypes. Altogether, these results are con-
sistent with a role for cis-acting regulatory variants influencing
levels of gene expression.
Cis control of MHC gene expression in LCLs and primary cells
To further test whether variation in expression could be attributed
to haplotypic effects, we investigated the three most significant
differentially expressed genes—ZFP57, HLA-DQA2, and HLA-DQB2
(Table 1). ZFP57 encodes a zinc finger protein involved in tran-
scriptional regulation and DNA methylation (Li et al. 2008) and is
located at the telomeric end of theMHC class I region.Wemapped
its quantitative expression in peripheral blood mononuclear cells
(PBMCs) of 93 healthy volunteers using 45,237 SNPs genotyped on
the Illumina HumanCVDv1 BeadChip (Keating et al. 2008). Strik-
ingly, this showed a highly significant association between ex-
pression of ZFP57 and the rs29228 SNP located 16.8 kb down-
stream from ZFP57 (P = 1.23 1014) (Fig. 3A,B). The COX cell line is
homozygous for the minor allele of the SNP associated with ex-
pression and when we tested three additional LCLs, only those
homozygous for the rare allele showedevidenceofZFP57 expression
(Fig. 3C). In addition, rs29228 is in complete linkage disequilibrium
with rs3129073, which is also significantly associated with ZFP57
expression (effect =1.088; P = 5.43 1030; rank = fourth) in LCLs
from an independent familial asthma cohort (Dixon et al. 2007).
There is evidence of association of theCOX
haplotype with type 1 diabetes, while mu-
tations of ZFP57 itself have been associated
with transient neonatal diabetes (Mackay
et al. 2008).
We also performed genome-wide
eQTL mapping for HLA-DQA2 and HLA-
DQB2 using the same cohort of healthy
volunteers. For both genes, we found sig-
nificantly associated SNP markers in
the MHC. For HLA-DQA2, rs2269423 was
the most significantly associated SNP in
the MHC, located 653 kb away from the
gene, and the sixth genome-wide (P =
2.13 3 104). Individuals possessing
a copy of the A allele showedhigher levels
of expression with consistent results seen
in the panel of six MHC-homozygous
LCLs for this SNP (Supplemental Fig. 8A).
Similarly, for HLA-DQB2, rs9469220 lo-
cated 65 kb downstream from the gene is
the best associated SNP in the MHC and
the seventhgenome-wide (P= 1.013 104)
(Supplemental Fig. 8B).
We specifically investigated the
SNP rs9264942 located 35 kb upstream of
HLA-C, which was previously reported to
be associatedwith expression ofHLA-C in
PBMCs (Thomas et al. 2009). Using the
MHCarray, we find that higher expression
of HLA-C is seen in QBL, which is homo-
zygous CC for this SNP compared to COX
and PGF, which are homozygous TT, con-
sistent with the previous report of higher
expression associated with possession of
the C allele. Moreover, when we genotyped our 96 healthy vol-
unteers by Sanger sequencing and looked at expression ofHLA-C at
the transcript level in PBMCs, we found that possession of a copy
of the C allele is associated with 22.6% higher expression ofHLA-C
(Mann Whitney, P = 0.023, two-tailed) (Supplemental Fig. 8C).
These results validate the use of homozygous LCLs to identify
haplotype-specific expression patterns. Although our study does
not rule out the involvement of trans-acting variants, the correla-
tion of differential expression with adjacent polymorphisms and
our findings from expression quantitative trait mapping are consis-
tent with several studies reporting a majority of cis eQTLs (Cheung
and Spielman 2009).
The extent of alternative splicing in the MHC
Alternative splicing is increased in the MHC compared to non-MHC genes
Alternative splicing (AS) is critical to the generation of transcript-
omic diversity and is known to be modulated by sequence varia-
tion with important implications for disease (Wang and Cooper
2007; Keren et al. 2010). Here we sought to investigate the extent
of haplotype-specific alternative splicing within the MHC. First,
we used the Affymetrix Exon 1.0 ST array hybridized with the PGF
samples (whose MHC sequence is the human reference) to estab-
lish the extent of AS in this region in comparison with the rest of
the genome. Absolute exon normalized intensities (NI) were de-
termined by subtracting the log2 exon intensity from the log2 gene
Table 1. Variation of gene expression between haplotypes
log2 (fold change)
Gene name Class COX vs. PGF QBL vs. PGF QBL vs. COX
Adjusted
P-value
ZFP57 I 2.77 0.00 2.76 1.22 3 1014
HLA-DPB2a II 3.19 3.02 0.17 2.89 3 1012
HLA-DQA2 II 2.45 1.62 0.82 1.91 3 1011
HLA-DQB2 II 2.74 2.58 0.16 3.21 3 1011
HLA-U a I 2.52 0.36 2.87 1.32 3 1010
TNF III 1.90 1.03 0.87 4.79 3 1010
HLA-DPB1 II 2.08 0.90 1.18 6.44 3 1010
RPL32P1 a II 1.52 1.19 0.33 2.07 3 1009
HLA-B I 0.06 1.19 1.13 6.59 3 1009
HLA-A I 1.51 1.86 0.35 2.30 3 1008
HLA-L a I 1.29 1.47 0.18 2.30 3 1008
XXbac-BPG254F23.6 II 1.59 1.59 0.00 2.50 3 1008
HCG22 I 1.56 1.26 0.30 2.96 3 1008
XXbac-BPG254F23.5 II 1.42 1.61 0.19 1.33 3 1007
LTA III 1.32 0.57 0.75 2.04 3 1007
NCR3 III 0.87 0.95 0.08 4.95 3 1007
HLA-F I 0.15 0.90 1.05 4.95 3 1007
HLA-DOA II 1.32 0.89 0.43 5.07 3 1007
TAP1 II 0.97 0.08 0.89 6.86 3 1007
LTB III 0.95 0.06 0.89 7.02 3 1007
LST1 III 0.18 0.48 0.66 9.42 3 1007
DAQB-335A13.8 I 0.61 0.02 0.63 1.12 3 1006
TCF19 I 1.11 0.62 0.49 1.49 3 1006
CLIC1 III 1.22 0.57 0.66 1.49 3 1006
HLA-DMA II 0.57 0.89 0.33 3.52 3 1006
BRD2 II 0.78 0.27 0.51 3.60 3 1006
NRM I 0.77 0.39 0.38 4.48 3 1006
HLA-C I 0.05 1.11 1.06 4.98 3 1006
PSMB9 II 0.42 0.29 0.71 6.05 3 1006
HCG27 I 0.56 0.06 0.50 7.01 3 1006
Top 30 genes showing significant differential expression between haplotypes after Benjamini-Hochberg
adjustment. For each cell line, the gene level intensity was computed from the signal intensity of the
probes matching uniquely and perfectly to its haplotype sequence.
aPseudogene.
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Table 2. Candidate genes for diseases associated with the HLA-A1-B8-DR3 (susceptibility to type 1 diabetes, systemic lupus erythematosus,
myasthenia gravis) and HLA-A3-B7-DR15 (susceptibility to multiple sclerosis, protection against type 1 diabetes) haplotypes
HLA-A1-B8-DR3 HLA-A3-B7-DR15
Class Gene name
Mean log2 (fold change)
COX vs. PGF/QBL Direction
Mean log2 (fold change)
PGF vs. COX/QBL Direction
I ZFP57 2.77 Up
ZDHHC20P1a 0.43 Up
DAQB-335A13.8 0.62 Up
IFITM4P a 0.98 Up
HCG4 a 0.43 Down
MICG a 0.49 Down
HLA-G 0.39 Up
HLA-T a 0.53 Up
HLA-K a 0.53 Down
HLA-U a 2.69 Down
HLA-A 1.68 Up
HCG4P5 a 0.60 Up
TRIM26 0.31 Up
HLA-L 1.38 Up
HCG18 0.60 Up
RPP21 0.31 Up
RANP1 a 0.62 Down
PRR3 0.37 Down
NRM 0.57 Up 0.58 Down
FLOT1 0.40 Up
IER3 0.58 Up
DDR1 0.44 Down
III VARS2 0.36 Down
HCG22 1.41 Up
TCF19 0.80 Up 0.86 Down
HCG27 0.53 Up
XXbac-BPG299F13.14 0.49 Up
HLA-S a 0.52 Up
MICB 0.52 Up
MCCD1 0.37 Up
DDX39B 0.53 Up
ATP6V1G2 0.36 Down
LTA 1.03 Up 0.94 Down
TNF 1.38 Up 1.46 Down
LTB 0.92 Down
LST1 0.42 Down
NCR3 0.91 Down
AIF1 0.63 Down
APOM 0.56 Down
CLIC1 0.94 Up 0.90 Down
HSPA1L 0.33 Up
HSPA1A 2.13 Up
DOM3Z 0.34 Up
PBX2 0.30 Up
II HLA-DRA 0.60 Up
HLA-DRB1 0.68 Up
HLA-DQB1 0.81 Up
XXbac-BPG254F23.5 1.52 Up
XXbac-BPG254F23.6 1.59 Up
HLA-DQA2 1.64 Down 2.03 Up
HLA-DQB2 2.66 Up
TAP2 0.79 Up
PSMB8 0.66 Up
XXbac-BPG246D15.8 0.67 Up 0.56 Down
PSMB9 0.57 Up
TAP1 0.93 Up
HLA-DMA 0.73 Up
BRD2 0.65 Up 0.53 Down
XXbac-BPG181M17.4 0.40 Up
HLA-DOA 0.87 Down 1.10 Up
HLA-DPA1 0.56 Up
HLA-DPB1 1.63 Down 1.49 Up
RPL32P1 a 0.93 Down 1.35 Up
HLA-DPB2 3.10 Up
HLA-DPA3 a 0.43 Down
aPseudogene.
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Figure 2. Distribution of differentially expressed (DE) probes versus polymorphic SNPs. Only probes shared by the three haplotypes were included. (A)
Three-haplotype comparison. (Upper panel) Significance level of DE probes for either unstimulated (blue) or stimulated (green) cells. The log10 of
significant adjusted P-values are plotted against the genomic coordinates. (Lower panel) Density curve of DE probes normalized using the number of
probes designed (upward)mirroring the density curve of polymorphic SNPs between the three cell lines (downward) for 350 10-kbwindows spanning the
MHC. Densities have been normalized. (B–D) Pairwise comparisons of COX versus PGF, QBL versus PGF, andQBL versus COX. For each pair, the log2 of the
intensity fold change (FC) is represented in the upper panel. For example, when expression is higher in COX than in PGF, the FC is set positive and an
orange bar is represented above the x-axis. Conversely, when expression is higher in PGF, the FC is negative and represented by a pink bar below the x-axis.
The density curves of DE probes and of SNPs polymorphic between both cells are plotted in the lower panel. (E ) Genomic context.
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intensity, positive and negative values indicating exon inclusion
and exclusion, respectively, with anNI value >1 indicating that the
exon is expressed at least twice more or less than the overall gene
level. The proportion of exons with NI values different from zero
was determined for MHC and other gene sets. This analysis re-
vealed that AS events were strikingly enriched in MHC genes com-
pared to non-MHC genes generally, or specifically to non-MHC
genes with an immune function (Fig. 4). This was true whether we
considered the number of spliced exons or the number of genes
with at least one splice event. Overall, 72.5% of the MHC genes
underwent AS of at least a twofold magnitude compared to 62.1%
of the non-MHC genes (Fig. 4A). To avoid potential bias due to the
number of annotated exons per gene, we determined the signifi-
cance of these observations by permutations on genes with at least
four annotated exons (median number in the genome) in either
Vega (Fig. 4B) or Ensembl databases (P# 13 104 forMHCvs. non-
MHC and MHC vs. non-MHC immune; not significant for non-
MHC immune vs. non-MHC non-immune) (Supplemental Table
6). The extent of AS in the MHC could therefore be considered
as a further means to increase diversity of gene expression
in this genomic region already characterized by its extreme
polymorphism.
The MHC haplo-spliceo-transcriptome
We next considered the extent to which alternative splicing varies
between haplotypes. To do this, gene and exon level expression of
genes were determined from the probes matching uniquely and
perfectly to each haplotype. This analysis showed that these AS
events also demonstrate haplotype-specific differences (Supple-
mental Table 7). In total, we found that 526 (23.9%) exons in the
MHC showed haplotypic differences, notably affecting classical
HLA genes such asHLA-DPB2,HLA-DQB2,HLA-C, orHLA-G. In the
latter, AS has been described as playing a critical role in immuno-
modulation, susceptibility to preeclampsia, and sensitivity to tumor
lysis by natural killer cells (Yao et al. 2005; Carosella et al. 2008).We
complemented our analysis at the exon level with splice junction
resolution in the class III region (where we designed junction
probes). We computed junction level intensity values, which were
then normalized against the gene intensity.We identified 27 out of
58 genes (46.6%) as showing haplotypic differences in AS (Sup-
plemental Table 8). A number of genes in this region are known
to undergo AS such as AIF1 (Hara et al. 1999). We validated the
array results for AIF1 by RT-PCR, both in terms of exon normal-
ized intensities and junction normalized intensities (P < 0.02 for
all junctions, ANOVA) with evidence of haplotypic differences
(Fig. 5).
Discussion
Our results provide the first high-resolution, strand-specific tran-
scriptional map of the MHC. We find that both intergenic tran-
scription and alternative splicing are abundant in the MHC and
that the transcript diversity mirrors the unusually high level of
polymorphism found in this region. Specifically, for common dis-
ease-associated haplotypes, we have been able to define transcrip-
tion at haplotype-specific resolution using MHC-homozygous
Figure 3. Expression quantitative trait mapping for ZFP57. Expression of ZFP57 was determined by quantitative real-time RT-PCR in peripheral blood
mononuclear cells of 93 healthy volunteers and analyzed for association using 45,237 SNPs enriched for immune and inflammatory genes. (A) Manhattan
plot showing a highly significant association for an SNP, rs29228, 16.8 kb centromeric to ZFP57. The horizontal dashed line indicates the genome-wide
threshold significance. The absence of other association with neighbor SNPs on chromosome 6 is not unexpected due to moderate SNP coverage in the
region and low level of linkage disequilibrium. (B,C ) Boxplots of ZFP57 gene expression relative to GAPDH depending on rs29228 genotype in 92
successfully genotyped individuals (Kruskal-Wallis test on genotypes, P = 6.7 3 1011) (B) or for MHC-homozygous lymphoblastoid cell lines (C ).
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LCLs. This has highlighted the extent of variation in gene ex-
pression that exists between haplotypes when a large contiguous
homozygous sequence is analyzed, in this case, a 3.5-Mb region
spanning the classical MHC. Haplotype-specific analysis is critical
to advance our understanding of the nature and consequences
of genetic variation within the diploid human genome. Given its
biological significance and wealth of disease associations, the full
haplotype-specific sequence for eight common haplotypes span-
ning the MHC were defined by the MHC Project (Stewart et al.
2004; Traherne et al. 2006; Horton et al. 2008). Here we comple-
ment this data with a haplotype-specific map of transcription in
which differentially expressed genes were quantified in the con-
text of phased sequence variants, allowing any regulatory variants
to exert allele-specific effects in the naturally occurring genomic
context. The use of MHC-homozygous LCLs avoids the confound-
ing effects normally encountered in analysis of the diploid genome
and provides a route map for further fine mapping and functional
analysis of observed MHC disease associations.
The transcriptional landscape we have described is likely to
vary in a context-specific manner, and it will be important to ex-
tend our approach to relevant cell/tissue types and conditions for
specific MHC-associated diseases. Nevertheless, the three LCLs we
used were our material of choice for these first studies of the MHC
transcription at a haplotype-specific resolution. Firstly, these cell
lines are MHC-homozygous for the disease-associated haplotypes
of interest, and we benefited from having available the full MHC
sequence for each, facilitating our approach as if we had been
studying mouse strains, thus avoiding the issue of recombination.
Secondly, linkage of expression phenotypeswas first demonstrated
in LCLs, proving these phenotypes are not artifactual. Since then,
most eQTL mapping studies have investigated that material with
reproducible findings (Stranger et al. 2007; Cheung and Spielman
2009; Montgomery et al. 2010; Pickrell et al. 2010). Thirdly, in the
MHCwe found that 87%of the genes in the region are expressed in
that cell type, making it a relevant choice for investigating differ-
ential expression between individuals. Finally, we proved with
ZFP57,HLA-DQA2,HLA-DQB2, andHLA-C that our findings could
be replicated in primary peripheral blood cells.
We have shown how a high-density tiling path array design
incorporating sequence diversity and splice junctions is a powerful
Figure 4. Extent of alternative splicing in the MHC. Absolute values of exon level intensities normalized against gene intensities [NI = log2(exon/gene)]
were computed from the median signal of the three PGF sample replicates hybridized to the Affymetrix Exon 1.0 ST array. Thus, absolute NI > 1 indicates
that the exon is expressed at least twicemore or less than the overall gene level. Mean percentage of exons (A) and of genes with at least one exon (B) with
NI value(s) exceeding the indicated thresholds for MHC (gray bars) and non-MHC genes (white bars). Error bars depict standard errors of the means of the
three replicates (C–E ) Comparisons of the median NIs (dashed vertical line) in the 131 MHC genes (C,E ) or in 733 non-MHC immune genes (D) having at
least four annotated exons in Vega with the density distribution of median NIs obtained in 10,000 random sets of similar numbers of non-MHC (C ), non-
MHC non-immune (D), and non-MHC immune (E ) genes.
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tool to help dissect the haplo-spliceo-transcriptome (Graveley
2008) of a large genomic region of interest. Like RNA-seq, our
array overcomes some major issues associated with commercial
expression arrays; notably, it accounts for underlying sequence
polymorphism, allows for identification of new transcribed re-
gions, and monitors splice events. Moreover, these microarrays
currently provide amuch less costly tool than RNA-seq to assess the
transcription status of a chromosomal region the size of the MHC,
although we recognize the greater dynamic range and allele-spe-
cific resolution of this technology (Wang et al. 2009). We have
Figure 5. Variation of splicing events in AIF1 between haplotypes. (A) Gene transcripts as they are annotated in Vega. (B) Barplots of all exon normalized
intensities (NI) for each cell line. The color code for each exon is indicated in the transcript scheme underneath. (C ) Barplots for the junction normalized
intensities (JNI). Donor and acceptor exons are represented on each half of the junction with the same color code as in B. If the junction is shared between
different transcripts, the corresponding site is depicted as a composite of all possible exons. (B,C ) Asterisks above barplots indicate the level of significance,
as listed in the caption, for differential expression between the three cell lines. For example, the isoform AIF1-002 tagged by the exon in orange is
proportionallymore represented inQBL and PGF than in COX. Conversely, the isoform AIF1-005 characterized by the junction between the brown and the
red exons is better represented in COX than in PGF and QBL.
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applied the MHC array to MHC-homozygous individuals, but the
custom array should also be informative when applied to hetero-
zygous samples. Here it will be necessary to know the DNA se-
quence or relevant genotypic information to select the correct
probes for analysis and interpret the data correctly. The tiling path
probe set can then be defined across the MHC by individual. At
positions where the individual is heterozygous, the average of the
two informative allele-specific probes can be taken.
Our findings that only 6% of the region is transcribed might
appear as a low figure. This, however, is the same order of magni-
tude as, for example, 4.6% of the total length of ENCODE regions
screened on tiling arrays (ENCODE Project Consortium 2007). That
31% of the TARs, representing 28.3% of total transcribed MHC se-
quence,were found in intergenic regions is also in linewith the 25%
recent estimate of ‘‘dark matter transcripts’’ obtained by RNA-seq
(Ponting and Belgard 2010) and is, however, of considerable in-
terest, given that theMHC region is the most gene-dense region of
the human genome. Their expression was overall low, which
might explain why we failed to detect haplotype-specific differ-
ences and correlation with SNPs localization, unlike for TARs in
genic areas. The biological significance of these TARs is unclear.We
have not investigated their processing, but the fact that of the 50%
localizing distantly (>10 kb) from annotated genes, the majority
colocalize withAlu sequences is particularly intriguing. It is known
that Alu sequences can be actively transcribed and may contribute
to the emergence of alternative splicing or even new genes and
pseudogenes (Deininger et al. 2003). Some classical HLA genes
have been postulated to derive from such repeat elements. The
intergenic TARs we detect might therefore reflect an ongoing process
of exonization of transposed elements leading to the emergence of
new MHC genes, also important for the regulation of existing genes
and therefore eventually for MHC-associated pathology.
It has been suggested that alternative splicing is a key mod-
ulator of immune gene expression (Lynch 2004), possibly leading
to antagonist effects as seen forMYD88 or CD44. A previous study
has revealed that up to 94%ofhumangenes are alternatively spliced
across 15 tissues tested fromdifferent individuals (Wang et al. 2008).
We found that in a single cell type from a single individual, 72.5%
of the MHC genes are alternatively spliced. Moreover, alternative
splicing is enriched among MHC genes compared to non-MHC
immune genes. We also demonstrate that alternative splicing is
related to the haplotypic structure. In the context of common
ancestral MHC haplotypes, one can thus imagine that alternative
splicing is used by evolution to generate more transcript diversity
in the MHC while preserving some of the haplotypic structure.
Consequences of such splicing patterns can lead to dramatic
consequences as already highlighted by mutations in the BTLN2
gene associated with sarcoidosis (Valentonyte et al. 2005).
Our study presents a proof of principle that, beyond standard
SNP-based eQTL mapping studies, it is possible to directly study
haplotype-specific gene expression at a high resolution for a 3.5-Mb
region and find striking differences. Our approach will be of value
in a generic sense for characterizing other genomic intervals
identified by GWAS or other approaches. Risk haplotypes are
ultimately associated to the phenotypes, and identifying genes
differentially expressed can reduce the number of genes to study
at the disease locus region.
For the MHC, this is of particular interest given the remark-
able number of associations with commondiseases reported, while
the fine mapping of functionally important regulatory variants
remains a challenge. That such important differences in gene ex-
pression could be detected by investigating only three haplotypes
supports the hypothesis that they play a role in the autoimmune
diseases associatedwith these haplotypes. Our data suggest a number
of candidate variants and gene transcripts for further characteriza-
tion. For example, Figure 1 presents a graphical overviewof the locus
showing differentially expressed genes by haplotype, while Table 2
lists 37 candidate genes potentially accounting for the association
of the HLA-A1-B8-DR3 haplotype with numerous diseases.
For the MHC, both structural and regulatory genetic variants
are important in determining disease susceptibility, and our ap-
proach to this region needs to consider such variants if causal re-
lationships are to be established. Our analysis has provided new in-
sights into how transcription differs between individuals across the
classical MHC, and our custom array can be used to quantify hap-
lotype-specific differences in related contexts such as DNA methyl-
ation or chromatin accessibility based on DNase hypersensitivity
(Sabo et al. 2006; Weber et al. 2007). As our knowledge of the com-
plexities of gene regulation continues to grow, it is important to
acknowledge how much remains to be understood and the need
for a more complete picture of gene expression beyond transcript
level analysis. At a mechanistic level, much attention has focused
onmodulation of transcriptional initiation, but sequence diversity
will impact in multifaceted ways on the whole process of tran-
scription and translation, as well as how chromatin is packaged
and gene expression coordinated at a local and global level within
the nucleus. It will be critical to establish the nature and basis of
individual epigenetic variation, defining how this may be modu-
lated by underlying DNA sequence variation as well as environ-
mental factors relevant to disease. We believe our analysis opens
the door to such studies and provides an important further step in
our quest to define the functional basis of the remarkable disease
associations found for this region of the genome.
Methods
Full methods and any associated references are available in the
Supplemental Material.
Samples
Lymphoblastoid cell lines (LCL)
COXwas obtained both fromThe International Histocompatibility
Working Group (IHW, ref 0922) and by the generosity of S. Marsh
and N. Mayor (Anthony Nolan Research Institute, UK). PGF and
QBL were purchased from the European Cell Culture Collection
(Salisbury, UK; ref 94050342 and 94070713). Chromosome integrity
was checked by FISH. In addition to chromosome 6 painting, the
AF129756BAC (The Sanger Institute) encompassingmost of the class
III region was used as a second probe to verify MHC integrity. Ge-
notypes of HLA classical molecules (HLA-A, B, C, DR, and DQ) were
verified by the Tissue Typing Laboratory in Oxford (Dr. Barnardo
Martin), while the homozygosity and genotypes of microsatellites
along the class III region (D6S272, D6S2800, MICA, TNFb, and
D6S2789) were checked as described before (Vandiedonck et al.
2004). Apart from D6S272, which showed heterozygosity for PGF,
all other markers showed the expected genotypes. Genotypes for
410 SNPs in the MHC region were also verified for COX, PGF, and
QBLusing a cardiovascular gene-centric 50K SNParray (humanCVD
bead array; Illumina) (Keating et al. 2008). With one exception
(rs562047 found G/C in QBL), all genotypes were those expected.
To follow up results on ZFP57, HLA-DQA2, HLA-DQB2, and HLA-C
expression, three additional MHC-homozygous cell lines—MANN/
MOU, DBB, and APD (IHW9050, 9052, 9291)—were studied, and
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their MHC genotypes were also checked with the cardiovascular
array (Keating et al. 2008).
PBMCs from healthy volunteers
PBMCs from healthy volunteers were recruited with cDNA pre-
pared as described in Fairfax et al. (2010). Their genomic DNAwas
extracted using Puregene kits (Gentra Systems, Inc.). Genotyping
on the humanCVD bead array was performed using genomic DNA
from the volunteers and homozygous LCLs DNA, as previously
described (Fairfax et al. 2010). For two specific SNPs not included on
the array—rs2269423 and rs9264942—genotyping was performed
by direct Sanger sequencing (primer sequences available on re-
quest). For some genes subsequently interrogated by expression
quantitative trait mapping, genotyping and/or gene expression
data were not available for all volunteers. The total numbers of
volunteers included for each gene analyzed are shown in the as-
sociated figure legends.
Design of the MHC array
The MHC array was designed for the Affymetrix platform (Affy-
metrix) using ad hoc algorithms as described in detail in the Sup-
plemental Methods. Criteria of uniqueness against the genome
and transcriptome and of structural conformation were consid-
ered. Known polymorphisms and segmental duplications have
been incorporated into the design.
Experimental procedures
Cell culture
Lymphoblastoid cells were grown in triplicate at a minimum den-
sity of 6 3 105 cells/mL in RPMI 1640 (Sigma, lot 16K2379) sup-
plemented with 10% Fetal Calf SerumGold (PAA, lot A64095-0537)
and 2 mM L-glutamine (PAA, lot M00406-0102) at 37°C in a 5%
CO2wet environment. Cultureswere stimulated or not for 6 hwith
200 nMphorbol 12-myristate 13 acetate (PMA; Sigma) and 125 nM
ionomycin (Sigma) and harvested at 83 105 to 13 106 cells/mL in
log growth phase. Volunteers’ peripheral blood mononuclear cells
(PBMC) were prepared as previously described (Fairfax et al. 2010).
RNA extraction
Total RNA was isolated using RNeasy midiprep kits (QIAGEN) in-
cluding on column DNase I digestion. Quantifications were done
by Nanodrop (ThermoScientific), and integrity was verified using
a 2100 Bioanalyzer (Agilent). All samples had a RNA integrity
number >9. Genomic DNA contamination was checked by real-
time PCR and was <0.1%.
Array experimental design
We hybridized samples from the unstimulated and stimulated
triplicate cultures of COX, PGF, and QBL LCLs to custom MHC ar-
rays, while only unstimulated samples were hybridized to com-
mercial Affymetrix Exon 1.0 ST arrays.
Sample labeling and array hybridization
We used the GeneChip Whole Transcript (WT) Sense Target La-
beling kit (Affymetrix), following the manufacturer’s instructions,
starting with 1.5 mg of total RNA and including the ribosomal RNA
depletion step (Ribominus kit; Invitrogen). Then, cDNA was syn-
thesized using randomhexamers tailed with a T7 promoter to avoid
39 bias, and the complementary strand of RNAwas generated by an
in vitro transcription reaction. Subsequently, a new first strand of
cDNA was synthesized, complementary to the initial cDNA, in the
same orientation as the mRNA and denoted ‘‘ccDNA.’’ It was frag-
mented (range 40–70 bases), end-labeled, and hybridized to the
MHCandGeneChipExon1.0 STarrays (Affymetrix) for 16h at 45°C
following the manufacturer’s instructions. Reduced RNA, cRNA
following IVT, and fragmented ccDNA were verified on a 2100
Bioanalyzer. Hybridized arrays were then washed and stained on
a GeneChip Fluidics 450 workstation (Affymetrix) using the
FS450_0001 protocol. The arrays were scanned on a GCS3000
Scanner (Affymetrix).
cDNA synthesis and RT-PCR for validation
cDNAwas synthesized using random hexamers and Superscript III
Reverse Transcriptase (RT) (Invitrogen) as per the manufacturer’s
instructions including control reactions without reverse tran-
scriptase for each sample. Quantitative PCR was performed on
three technical replicates using SYBR Green Supermix (Bio-Rad)
on an iQ Cycler (Bio-Rad). PCR efficiency was determined using
serial dilutions of pooled cDNAs from COX, PGF, and QBL cells.
Melt curve analysis was performed for gene-specific primer sets.
Relative gene transcript levels were determined by the DDCt
method. Primer sequences are available upon request.
Array signal processing
Custom MHC array signals
Custom MHC array signals were processed using an in-house
pipeline under R and Bioconductor environment and using Perl
scripts as detailed in the Supplemental Methods. Briefly, after
preprocessing all probes, tiling and junction probes were analyzed
independently. Tiling path analysis was conducted to determine
the extent of transcription on the shared path and on each of the
alternate paths. Transcription within a gene was assessed by the
inclusion of at least one TAR at a FDR of 5%. Alternative splicing
was evaluated on each of the alternate paths both at the exon level
and, for theMHC class III region, at the splice junction level. Exon
and junction intensities were normalized against the gene level
intensities.
Exon array signals
Exon array signals were processed using Affymetrix Power Tools,
and R scripts (see Supplemental Methods). Briefly, probe-level
analysis was carried out for cross-platform validation, while gene
level and alternative splicing analyses were performed using cus-
tom CDF files from the Microarray Lab (http://brainarray.mbni.
med.umich.edu/).
Quality controls
Quality controls are given in the Supplemental Methods.
Statistical analyses
All statistical analyses, including distribution of the TARs; com-
parison of expression between haplotypes; correlation of differ-
entially expressed probeswith SNP distribution; eQTLmapping for
ZFP57, HLA-DQA2, and HLA-DQB2; and analysis of the extent of
the MHC splicing were performed using R, Perl, and PLINK as
provided in detail in the Supplemental Methods.
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